TG

Tredegar Corporation 2004 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2004. Tredegar Corporation operates through three primary segments: Film Products (plastic films, elastics, and nonwovens for personal care and packaging), Aluminum Extrusions (soft-alloy extrusions for construction and industrial markets), and Therics (a biotechnology subsidiary developing bone graft substitutes). The company sold its venture capital investment portfolio in 2003, and results from these activities are reported as discontinued operations.

Key Financial Metrics (2004)

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 17% to $861.2 million, driven by higher volume and selling prices in both Film Products and Aluminum Extrusions.
• Profitability: Net income turned positive ($29.2 million) compared to a net loss of $26.4 million in 2003. This improvement was aided by a $2.9 million gain from discontinued operations (reversal of tax contingencies) and a $4.0 million tax benefit from the reversal of income tax accruals.
• Segment Performance:
  • Film Products: Operating profit from ongoing operations declined slightly to $43.3 million (from $45.7 million) due to higher resin costs and the loss of domestic backsheet business, partially offset by new product sales.
  • Aluminum Extrusions: Operating profit surged 50% to $22.6 million due to operating leverage and pricing improvements, despite a $2.4 million adverse impact from the Canadian dollar appreciation.
  • Therics: Recorded an operating loss of $9.8 million on $380,000 in revenue as it launched initial bone graft products.
• Restructuring Costs: The company incurred $23.0 million in charges related to plant shutdowns, asset impairments, and restructurings, including the planned closure of the Aurora, Ontario aluminum plant and the New Bern, North Carolina film plant.

Guidance, Outlook, and Risks

• Outlook: Management expects continued volume growth in Aluminum Extrusions. For Film Products, growth is anticipated in new apertured, elastic, and protective films. Capital expenditures for 2005 are projected at approximately $50 million.
• Therics Strategy: Sales and marketing for Therics are evolving slower than expected. Management took steps in early 2005 to reduce the expected quarterly loss rate from $2.5 million to $2.0 million and is exploring collaborations to accelerate market penetration.
• Key Risks:
  • Customer Concentration: Procter & Gamble (P&G) accounted for 27% of net sales in 2004. A significant reduction in sales to P&G would have a material adverse effect.
  • Raw Material Volatility: Profit margins are sensitive to polyethylene resin and aluminum prices. While pass-through agreements cover ~65% of sales, there is a 90-day lag that can pressure near-term profits if costs rise faster than selling prices.
  • Foreign Currency: Appreciation of the Canadian dollar negatively impacts Aluminum Extrusions profits, while Euro appreciation had a positive impact on Film Products.

Investor Verification Checklist

• P&G Dependency: Verify the stability of the relationship with Procter & Gamble, which represents over a quarter of total revenue.
• Resin Cost Pass-Through: Monitor the effectiveness of cost-sharing agreements in offsetting rising polyethylene resin prices, particularly given the 90-day lag.
• Therics Burn Rate: Assess the timeline for Therics to reach profitability and the success of its new collaborations to reduce the $2 million quarterly loss target.
• Restructuring Execution: Confirm the completion of the Aurora and New Bern plant shutdowns and the realization of the projected $4 million in annual cost savings.
• Debt Covenants: Review the leverage ratio (1.27x) and interest coverage ratio (16.43x) to ensure continued compliance with the credit agreement covenants.